Corvus Pharmaceuticals, Inc. Increase (Decrease) in Other Current Assets
Corvus Pharmaceuticals, Inc. (CRVS) reported Increase (Decrease) in Other Current Assets of $858.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentAssets · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2026-06-30 was -$7.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2026-03-31 was $865.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2025-12-31 was $3.00K, a 99.21% decline year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for the quarter ending 2025-09-30 was $226.00K, a 83.74% increase year-over-year.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2025 was $223.00K, a 58.93% decline from fiscal 2024.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2024 was $543.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2023 was -$40.00K.
- Corvus Pharmaceuticals, Inc. increase (decrease) in other current assets for fiscal 2022 was -$107.00K.
| Period end | Increase (Decrease) in Other Current Assets 3 month | Increase (Decrease) in Other Current Assets 6 month | Increase (Decrease) in Other Current Assets 9 month | Increase (Decrease) in Other Current Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $858.00K 10-Q · filed 2026-08-06 | $861.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $865.00K 10-Q · filed 2026-05-07 | $868.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.09M derived: sum of 3 quarters · filed 2026-05-07 | $1.09M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $229.00K derived: sum of 2 quarters · filed 2026-03-12 | $226.00K derived: sum of 3 quarters · filed 2026-08-06 | $223.00K 10-K · filed 2026-03-12 |
| 2025-09-30 | $226.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $223.00K derived: sum of 2 quarters · filed 2026-08-06 | $220.00K 10-Q · filed 2025-11-04 | $600.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$6.00K 10-Q · filed 2026-08-06 | $374.00K derived: sum of 3 quarters · filed 2026-08-06 | $497.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$3.00K 10-Q · filed 2026-05-07 | $377.00K derived: sum of 2 quarters · filed 2026-05-07 | $500.00K derived: sum of 3 quarters · filed 2026-05-07 | |
| 2024-12-31 | $380.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $503.00K derived: sum of 2 quarters · filed 2026-03-12 | $543.00K 10-K · filed 2026-03-12 | |
| 2024-09-30 | $123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $163.00K 10-Q · filed 2025-11-04 | ||
| 2024-06-30 | $40.00K 10-Q · filed 2025-08-07 | |||
| 2023-12-31 | -$40.00K 10-K · filed 2026-03-12 | |||
| 2022-12-31 | -$107.00K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |